Efficacy observation of bevacizumab combined with hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with malignant ascites
10.3760/cma.j.cn115355-20200413-00196
- VernacularTitle:贝伐珠单抗联合腹腔热灌注化疗治疗胃癌伴恶性腹腔积液效果观察
- Author:
Xia WANG
1
;
Runxue JIANG
Author Information
1. 河北省唐山弘慈医院肿瘤科 063000
- From:
Cancer Research and Clinic
2020;32(10):701-704
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical effect of bevacizumab combined with hyperthermic intraperitoneal chemotherapy (HIPEC) on gastric cancer with malignant ascites.Methods:The data of 96 gastric cancer patients with malignant ascites in Tangshan People's Hospital in Hebei Province from August 2017 to December 2019 were retrospectively analyzed. The patients were divided into bevacizumab+HIPEC group (38 cases) and routine intraperitoneal chemotherapy group (58 cases). Both groups received oral chemotherapy with S-1. The serum tumor marker carcinoembryonic antigen (CEA) level, carbohydrate antigen 199 (CA199) level, objective response rate (ORR), disease control rate (DCR), quality of life (QOL) improvements, and occurrence of adverse reactions were compared between the two groups after they were treated for two courses.Results:Serum CEA and CA199 levels in the bevacizumab+HIPEC group were lower than those in the routine intraperitoneal chemotherapy group [(16±11) ng/ml vs. (24±14) ng/ml, (39±25) U/ml vs. (51±26) U/ml)], and the differences were statistically significant ( t = -2.962, P = 0.004; t = -2.361, P = 0.020). The ORR, DCR and improvement rate of QOL in the bevacizumab+HIPEC group were higher than those in the routine intraperitoneal chemotherapy group [63.2% (24/38) vs. 41.4% (24/58), 92.1% (35/38) vs. 75.9 % (44/58), and 78.9% (30/38) vs. 53.4% (31/58)], and the differences were statistically significant (all P < 0.05). The difference in the incidence of adverse reactions between the two groups was not statistically significant (all P > 0.05). Conclusion:Bevacizumab combined with HIPEC is a safe and effective approach for gastric cancer patients with malignant ascites.
